Middle East Point of Care Molecular Diagnostics Market (2025 - 2033)

Market Size & Trends

The Middle East point of care molecular diagnostics market size was valued at USD 273.5 million in 2024 and is projected to reach USD 463.0 million by 2033, growing at a CAGR of 6.13% from 2025 to 2033. The Middle East and Africa (MEA) region encompasses countries with both advanced and emerging healthcare systems, offering a diverse landscape for point-of-care (POC) molecular diagnostics. Well-established healthcare markets, such as Saudi Arabia and the UAE, provide streamlined regulatory pathways, robust logistics, and advanced laboratory networks that support market entry and expansion.

Historically, the region has faced significant challenges with communicable diseases such as malaria and typhoid, and events like the Middle East Respiratory Syndrome (MERS) outbreak in 2015 heightened awareness of the need for rapid molecular diagnostics. The COVID-19 pandemic further accelerated adoption, as the Middle East saw an exponential rise in confirmed cases during early 2020, driving demand for portable and near-patient testing technologies.

Target Disease Prevalence

Governments and private healthcare providers in MEA are strategically investing in infrastructure expansion, from upgrading tertiary hospitals to increasing the number of community-based clinics. These initiatives align with the integration of advanced POC molecular testing platforms capable of delivering fast and accurate results without reliance on centralized laboratories. Economic growth in several Gulf countries, including the UAE, Kuwait, and Qatar, is fueling higher healthcare spending, enabling the adoption of premium diagnostics for infectious diseases, chronic conditions, and sexually transmitted infections (STIs). Moreover, increasing patient awareness, higher purchasing power, and the shift toward preventive and personalized healthcare are expected to sustain market growth in the forecasted period.

In Saudi Arabia, government-led Vision 2030 initiatives emphasize localized manufacturing of molecular diagnostics and expanding public-private partnerships, creating a favorable market for POC platforms in both hospital and community health settings. The UAE is emerging as a regional innovation hub, with AI-enabled diagnostic platforms and ultra-rapid molecular testing solutions developed domestically, such as paper-based devices delivering results in under 10 minutes. Kuwait continues to invest in upgrading laboratory networks, with a growing share of testing shifting toward decentralized formats to improve patient turnaround times. Qatar is channeling resources into early disease detection programs, integrating POC molecular systems into primary care to address chronic and infectious disease burdens. Oman is adopting molecular point-of-care solutions in both urban and rural clinics, driven by national programs targeting respiratory infections, tuberculosis, and other high-prevalence conditions. Collectively, these developments position the Middle East as a rapidly advancing market for point-of-care molecular diagnostics, with strong governmental support and a growing appetite for cutting-edge healthcare technologies.

The UAE is witnessing a rise in the adoption of POC testing due to an increase in government initiatives aimed at the promotion of regular screening activities for cancer and other chronic diseases. For instance, the Ministry of Health and Prevention in the UAE regularly holds breast cancer screening programs, while the Department of Health-Abu Dhabi recommends & encourages frequent screening. Furthermore, the Ministry of Health & Prevention has launched several programs, such as the National Strategy for Fighting Diabetes, for reducing diabetes prevalence in the country.

Market Concentration & Characteristics

Innovation is high in the point-of-care molecular diagnostics space, driven by the need for faster, more accurate, and portable testing solutions. Advancements such as microfluidic cartridges, smartphone-based readers, and isothermal amplification improve diagnostic speed and sensitivity. In June 2025, researchers at NYU Abu Dhabi unveiled the RCP-Chip, a revolutionary paper-based diagnostic capable of detecting infectious diseases in under 10 minutes without requiring a laboratory setup or specialist staff. This breakthrough promises to transform testing accessibility in remote or resource-constrained environments, paving the way for scalable, ultra-rapid point-of-care molecular diagnostics. Complementing this innovation, the 5th POCT Advances Conference hosted on 10 May 2025 at the Cleveland Clinic Abu Dhabi served as a high-level forum discussing operational excellence, pharmacy integration in POCT, and emerging technologies. The event reinforced the region’s strategic push toward embedding next-generation POC molecular diagnostics across healthcare settings.

Mergers and acquisitions are moderately active, with larger diagnostic firms acquiring startups to enhance molecular testing portfolios. These deals often focus on integrating novel technologies or expanding into underserved markets. Strategic collaborations between diagnostics and digital health firms are also rising, helping accelerate R&D and improve platform interoperability.

Regulatory frameworks across the Middle East play a decisive role in shaping the adoption and commercialization of point-of-care (POC) molecular diagnostics. Countries such as Saudi Arabia, UAE, Qatar, Kuwait, and Oman maintain stringent oversight through their respective health authorities, including the Saudi Food and Drug Authority (SFDA), the UAE Ministry of Health and Prevention (MOHAP), and Qatar’s Ministry of Public Health. These bodies regulate device approval, quality standards, and post-market surveillance to ensure that diagnostic products meet safety, accuracy, and reliability benchmarks. The approval processes have become more streamlined in recent years, with accelerated pathways introduced for high-priority public health needs, particularly during outbreaks such as COVID-19 and MERS.

Product expansion has become a central strategy for companies competing in the Middle East point-of-care (POC) molecular diagnostics market, as healthcare providers increasingly demand versatile, rapid, and accurate testing solutions for a broad spectrum of clinical needs. Manufacturers are diversifying their test menus to cover a wider range of pathogens and medical conditions, extending beyond traditional infectious disease panels to include oncology, hematology, prenatal screening, and endocrinology.

Regional expansion is emerging as a key growth strategy for companies in the Middle East point-of-care (POC) molecular diagnostics market, driven by increasing healthcare investments, rising disease burden, and government-led modernization of diagnostic infrastructure. Multinational and regional players are actively extending their presence beyond primary hubs like Saudi Arabia and the UAE to include high-potential markets such as Kuwait, Qatar, and Oman. These countries are witnessing accelerated healthcare transformation under national vision programs, which prioritize rapid diagnostics to improve disease surveillance and patient outcomes.

Application Insights

On the basis of application, the infectious disease segment accounted for the largest market share of 47.96% in 2024, driven by persistent public health priorities such as tuberculosis control, respiratory virus surveillance, and sexually transmitted infection (STI) management. This dominance is reinforced by regional health ministries’ ongoing investment in rapid testing capabilities for outbreak management, especially in Gulf Cooperation Council (GCC) countries that aim to strengthen pandemic preparedness. In 2024, countries such as Saudi Arabia and the UAE have expanded procurement of multiplex molecular test kits that can identify multiple pathogens simultaneously, reducing patient turnaround time and limiting disease spread. The region’s high prevalence of infectious diseases like MERS-CoV, seasonal influenza, and hepatitis further strengthens the case for decentralized, rapid diagnostic tools.

The oncology segment is expected to be the most lucrative application area in the point-of-care molecular diagnostics market, driven by rising cancer incidence, particularly breast, colorectal, and prostate cancers, across the Middle East has increased demand for molecular tools capable of detecting specific genetic mutations and biomarkers at or near the patient’s location. Governments are pushing early detection programs, while private healthcare providers are investing in liquid biopsy and rapid mutation analysis technologies for more personalized treatment pathways. The shift toward outpatient cancer management has created opportunities for POC systems in oncology clinics and specialty centers, enabling quicker therapy decisions. This trend is also supported by increasing awareness campaigns and regional collaborations with global oncology diagnostics companies to integrate compact, high-precision devices into everyday clinical practice.

Technology Insights

PCR-based technologies held the largest share of 66.38% in 2024. Their continued dominance stems from decades of proven reliability, combined with ongoing miniaturization and automation that allow PCR to be deployed beyond central laboratories. Portable PCR platforms are now capable of delivering results in under an hour, a capability that has proven invaluable during COVID-19, MERS-CoV outbreaks, and seasonal flu surges. In 2024, new PCR-based respiratory pathogen panels have been rolled out in the UAE, enabling clinicians to differentiate between viral and bacterial infections in emergency departments, thus optimizing antibiotic stewardship.

The genetic sequencing-based point-of-care molecular diagnostics segment is expected to grow at the fastest rate during the forecast period. These platforms allow clinicians to analyze entire genomes or targeted gene panels directly at the patient site, unlocking possibilities for personalized medicine at an unprecedented speed. While adoption is still emerging, recent pilot projects in Qatar and Oman are using sequencing-based POC tools for rare disease diagnosis and oncology mutation profiling. Advancements in nanopore and other portable sequencing technologies are making it feasible to generate actionable genetic data within hours, even in decentralized locations. As costs continue to fall and device usability improves, sequencing-based diagnostics are poised to transform how genetic information is integrated into routine patient care in the Middle East.

Test Location Insights

In 2024, the over-the-counter (OTC) diagnostics segment held the highest share of 52.62%, driven by increasing consumer demand for rapid self-testing solutions. Rising health awareness, combined with proactive government health campaigns, has normalized self-testing for conditions such as COVID-19, influenza, and certain STIs. Pharmacies in Saudi Arabia and the UAE have expanded their OTC test kit offerings, enabling consumers to purchase rapid molecular diagnostic kits for home use without a prescription.

The point-of-care test location segment is expected to grow at the fastest rate during the forecast period. This trend is evident in rural and remote regions of Oman and Kuwait, where deploying portable molecular diagnostic devices in clinics and mobile health units ensures timely access to accurate test results. Hospitals are increasingly integrating POC molecular tools into outpatient departments, emergency rooms, and specialized care units to accelerate diagnosis and treatment.

End-use Insights

In 2024, the decentralized labs segment held the highest share of 42.76% in the Middle East point-of-care molecular diagnostics market. Their advantage lies in offering high-throughput testing capabilities while being strategically located closer to patient populations, reducing sample transport times. Many private hospital networks in the UAE and Saudi Arabia have established decentralized labs within their outpatient facilities, allowing same-day turnaround for both infectious disease panels and oncology biomarker testing.

The home care segment is expected to grow at the fastest CAGR over the forecast period. The caregivers and healthcare providers increasingly recognize the value of at-home testing solutions for managing chronic and acute health conditions. This shift has been fueled by rising consumer awareness, advances in portable molecular testing technology, and supportive healthcare policies promoting decentralization of diagnostics.

Key Middle East Point of Care Molecular Diagnostics Companies Insights

Key players operating in the Middle East point of care molecular diagnostics market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.

Recent Developments

• In July 2025, Dubai Health and GE HealthCare entered a strategic Memorandum of Understanding to elevate point-of-care ultrasound (POCUS) training and application across the MENA region. This partnership officially designates the Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) as a POCUS Education Center of Excellence, empowering it to lead regional clinical education.

• In February 2023, Digital Diagnostics Inc. and Tamer Healthcare announced a partnership. This collaboration focuses on distributing IDx-DR, an AI system for diagnosing diabetic retinopathy at the point of care. This showcases the potential and the way for wider adoption of other AI-powered POC diagnostic tools.

• In September 2022, Unitaid announced invested USD 30 million to accelerate the introduction of advanced diagnostic technologies, which would enhance screening efforts and expand testing availability at lower tiers of the healthcare system.

• In April 2022, PixCell Medical partnered with Dubai-based United Makgroup Technologies L.L.C. for the distribution of its rapid hematology testing HemoScreen solutions in the UAE. Similarly, in December 2020, Israel’s Sight Diagnostics partnered with Phoenix Capital for the distribution of its Sight OLO blood diagnostics devices to medical centers in the UAE.

Middle East Point of Care Molecular Diagnostics Market